ADJUNCTIVE ZIPRASIDONE IN OVERWEIGHT AND OBESE PATIENTS WITH BIPOLAR DISORDER

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This research study will evaluate treatment-associated changes in insulin sensitivity and blood lipids in overweight and obese patients receiving adjunctive ziprasidone, following a switch from other previously used medications. This study will be conducted in conjunction with a separate treatment study of ziprasidone. Oral glucose tolerance testing will be conducted at baseline and at the end of a 12-week trial of ziprasidone. The investigators hope to gather information on insulin sensitivity and blood lipids in obese and overweight bipolar patients who switch from medications associated with weight gain (i.e. olanzapine, risperidone, quetiapine, aripiprazole, lithium, or valproate) to one thought to be more weight-neutral (ziprasidone). To date, it is unclear whether treatment-associated changes in body weight are related to changes in insulin resistance, glucose tolerance, dyslipidemia, and other symptoms of insulin resistance syndrome.